Ringer's acetate better for patients with severe sepsis

June 28, 2012
Ringer's acetate better for patients with severe sepsis
Fluid resuscitation with hydroxyethyl starch 130/0.4 for patients with severe sepsis leads to an increased risk of death at day 90 and an increased likelihood of requiring renal-replacement therapy, compared with Ringer's acetate, according to a study published online June 27 in the New England Journal of Medicine.

(HealthDay) -- Fluid resuscitation with hydroxyethyl starch (HES) 130/0.4 for patients with severe sepsis leads to an increased risk of death at day 90 and an increased likelihood of requiring renal-replacement therapy, compared with Ringer's acetate, according to a study published online June 27 in the New England Journal of Medicine.

Anders Perner, M.D., Ph.D., from Rigshospitalet in Copenhagen, Denmark, and colleagues randomly assigned 798 participants with severe sepsis participating in a multicenter trial to fluid resuscitation in the with 6 percent HES 130/0.4 or Ringer's acetate (up to 33 mL per kilogram of ideal body weight per day).

The researchers found that, at 90 days following randomization, 201 of 398 patients assigned to HES 130/0.4 had died, compared to 172 of 400 patients assigned to Ringer's acetate (relative risk [RR], 1.17; 95 percent confidence interval [CI], 1.01 to 1.36), and one patient in each group had end-stage . In the HES 130/0.4 group, 87 patients (22 percent) were treated with renal replacement therapy in the 90-day period, compared to 65 patients (16 percent) in the Ringer's acetate group (RR, 1.35; 95 percent CI, 1.01 to 1.80), and 38 and 25 patients, respectively, had severe bleeding (RR, 1.52; 95 percent CI, 0.94 to 2.48).

"Patients with severe assigned to fluid resuscitation with HES 130/0.4 had an increased risk of death at day 90 and were more likely to require renal-replacement therapy, as compared with those receiving Ringer's acetate," the authors write.

Perner disclosed receiving grant support from Fresenius Kabi.

More information: Abstract
Full Text

Related Stories

Cancer risk up in bilateral retinoblastoma survivors

February 23, 2012

(HealthDay) -- For survivors of bilateral retinoblastoma (Rb), family history is associated with an increased risk of second cancers (SCs), especially melanoma, according to a study published online Feb. 21 in the Journal ...

Recommended for you

Experimental MERS vaccine shows promise in animal studies

July 28, 2015

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. ...

Can social isolation fuel epidemics?

July 21, 2015

Conventional wisdom has it that the more people stay within their own social groups and avoid others, the less likely it is small disease outbreaks turn into full-blown epidemics. But the conventional wisdom is wrong, according ...

Lack of knowledge on animal disease leaves humans at risk

July 20, 2015

Researchers from the University of Sydney have painted the most detailed picture to date of major infectious diseases shared between wildlife and livestock, and found a huge gap in knowledge about diseases which could spread ...

IBD genetically similar in Europeans and non-Europeans

July 20, 2015

The first genetic study of inflammatory bowel disease (IBD) to include individuals from diverse populations has shown that the regions of the genome underlying the disease are consistent around the world. This study, conducted ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.